Pharmaceutical

Citius aims to bounce back from Lymphir setback

Citius Pharmaceuticals’ CEO detailed plans to launch its lymphoma therapy Lymphir in Autumn 2024, as it awaits a PDUFA date.

Mar 7, 2024 - 18:00
Citius aims to bounce back from Lymphir setback
Citius Pharmaceuticals’ CEO detailed plans to launch its lymphoma therapy Lymphir in Autumn 2024, as it awaits a PDUFA date.
Read the original article

Tags:

Previous Article

CTS Europe: The roadmap for generative AI in the pharma industry

Next Article

Sionna raises $182m to double down in cystic fibrosis drug development

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AstraZeneca posts $2.18bn profit after tax in Q1 2024

AstraZeneca posts $2.18bn profit after tax in Q1 2024

Apr 27, 2024

As states ban gender-affirming care, Minnesota aims to be a refuge for trans youth

As states ban gender-affirming care, Minnesota aims to ...

Mar 28, 2023

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s booming business, & a long-awaited drug approval

Listen: Explaining the E.U.’s pharma overhaul, Lilly’s ...

Apr 27, 2023